ZMC(SH:600216) Sou Hu Cai Jing·2025-07-29 10:48Group 1 - The core viewpoint of the news highlights the financial performance and stock activity of Zhejiang Pharmaceutical as of July 29, 2025, with a closing price of 15.46 yuan, reflecting a 1.38% increase [1] - The company reported total revenue of 2.255 billion yuan for Q1 2025, showing a year-on-year growth of 0.28%, while net profit attributable to shareholders reached 409 million yuan, a significant increase of 273.08% [1] - The company has a strong liquidity position with a current ratio of 2.854 and a quick ratio of 1.999, alongside a low debt-to-asset ratio of 19.51% [1] Group 2 - Zhejiang Pharmaceutical has made investments in 28 companies and participated in 82 bidding projects, indicating active engagement in business expansion [2] - The company holds 190 trademark registrations and 27 patents, showcasing its commitment to intellectual property and innovation [2] - Additionally, the company possesses 46 administrative licenses, reflecting its compliance and operational capabilities in the pharmaceutical industry [2]